Tempus AI, Inc. TEM

Company Overview

Tempus AI, Inc. is a technology-driven precision medicine company that applies artificial intelligence and advanced analytics to clinical and molecular data to support personalized healthcare. The company operates at the intersection of healthcare, biotechnology, and artificial intelligence, focusing primarily on oncology and, to a growing extent, neuropsychiatric and other complex diseases. Its core value proposition is the aggregation and analysis of large-scale, multimodal clinical and genomic datasets to inform diagnosis, treatment selection, and clinical research.

Tempus AI was founded in 2015 by Eric Lefkofsky with the objective of closing the gap between data generation and data utilization in medicine. The company has evolved from a genomics-focused diagnostics provider into an integrated data and analytics platform supporting physicians, researchers, and life sciences companies. Tempus AI became a publicly traded company in June 2024 following its initial public offering and is listed on the Nasdaq under the ticker symbol TEM.